In osteoarthritis (OA), the alterations in joint tissues are numerous and involve morphological, biochemical and metabolic changes and an upregulation of the inflammatory pathways. The focus of this article is a brief narrative review of the effects of diacerein, an antirheumatic drug from the anthraquinone chemical class, and its active metabolite, rhein, on the factors that participate in the complex interaction between OA tissues and cells leading to the progression of joint structural changes.
Alvarez-Soria, M.A., Herrero-Beaumont, G., Sanchez-Pernaute, O., Bellido, M. and Largo, R. ( 2008) Diacerein has a weak effect on the catabolic pathway of human osteoarthritis synovial fibroblast-comparison to its effects on osteoarthritic chondrocytes. Rheumatology (Oxford) 47: 627-633.
2.
Berthiaume, M.J., Raynauld, J.P., Martel-Pelletier, J., Labonté, F., Beaudoin, G., Bloch, D.A. et al. (2005) Meniscal tear and extrusion are strongly associated with the progression of knee osteoarthritis as assessed by quantitative magnetic resonance imaging. Ann Rheum Dis64: 556-563.
3.
Blanco, F.J., Guitian, R., Vazquez-Martul, E., de Toro, F.J. and Galdo, F.(1998) Osteoarthritis chondrocytes die by apoptosis. A possible pathway for osteoarthritis pathology. Arthritis Rheum41: 284-289.
4.
Boileau, C., Tat, S.K., Pelletier, J.P., Cheng, S. and Martel-Pelletier, J. ( 2008) Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: a possible mechanism for a protective effect against subchondral bone remodelling. Arthritis Res Ther10: R71.
5.
Bordji, K., Grillasca, J.P., Gouze, J.N., Magdalou, J., Schohn, H., Keller, J.M. et al. (2000) Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) alpha and gamma and retinoid Z receptor in cartilage. PPARgamma activation modulates the effects of interleukin-1beta on rat chondrocytes . J Biol Chem275: 12243-12250.
6.
Brandt, K.D. ( 2006) Studies in animal models of osteoarthritis as predictors of a structure-modifying effect of diacerhein in humans with osteoarthritis . Biorheology43: 589-594.
7.
Brandt, K.D., Smith, G., Kang, S.Y., Myers, S., O’Connor, B. and Albrecht, M. ( 1997) Effects of diacerhein in an accelerated canine model of osteoarthritis. Osteoarthritis Cartilage5: 438-449.
8.
Colville-Nash, P.R. ( 2002) Comparison of the pharmacologic effect of diacerein and a selective COX-2 inhibitor in the mouse induced-granuloma model. Presse Med31: 4S16-4S17 (abstract).
9.
Couchourel, D., Aubry, I., Delalandre, A., Lavigne, M., Martel-Pelletier, J., Pelletier, J.-P. et al. (2009) Altered mineralization of human osteoarthritic osteoblasts is due to abnormal collagen type 1 production. Arthritis Rheum60: 1438-1450.
10.
Domagala, F., Martin, G., Bogdanowicz, P., Ficheux, H. and Pujol, J.P. ( 2006) Inhibition of interleukin-1beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappaB and AP-1: potential mechanism for Diacerein effects in osteoarthritis. Biorheology43: 577-587.
11.
Dougados, M., Nguyen, M., Berdah, L., Mazieres, B., Vignon, E. and Lequesne, M. ( 2001) Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum44: 2539-2547.
12.
Fahmi, H., Di Battista, J.A., Pelletier, J.P., Mineau, F., Ranger, P. and Martel-Pelletier, J. ( 2001) Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum44: 595-607.
13.
Fahmi, H., Pelletier, J.P. and Martel-Pelletier, J. ( 2002a) PPARgamma ligands as modulators of inflammatory and catabolic responses on arthritis. An overview. J Rheumatol29: 3-14.
14.
Fahmi, H., Pelletier, J.P., Mineau, F. and Martel-Pelletier, J. ( 2002b) 15d-PGJ(2) is acting as a ‘dual agent’ on the regulation of COX-2 expression in human osteoarthritic chondrocytes. Osteoarthritis Cartilage10: 845-848.
15.
Fahmi, H., Pelletier, J.P., Di Battista, J.A., Cheung, H.S., Fernandes, J. and Martel-Pelletier, J. ( 2002c) Peroxisome proliferator-activated receptor gamma acitvators inhibit MMP-1 production in human synovial fibroblasts by reducing the activity of the activator protein 1. Osteoarthritis Cartilage10: 100-108.
16.
Fedeli, S. ( 1988) Livelli plasmatici di Diacerina nell’huomo anziano dopo somministrazioni repetute del farmaco a posologie diverse. Laboratoires NEGMA-PROTER. Study report, July 1988.
17.
Felisaz, N., Boumediene, K., Ghayor, C., Herrouin, J.F., Bogdanowicz, P., Galerra, P. et al. (1999) Stimulating effect of diacerein on TGF-beta1 and beta2 expression in articular chondrocytes cultured with and without interleukin-1 . Osteoarthritis Cartilage7: 255-264.
18.
Fidelix, T.S., Soares, B.G. and Trevisani, V.F. ( 2006) Diacerein for osteoarthritis. Cochrane Database Syst RevCD005117.
19.
Ghosh, P., Xu, A., Hwa, S.Y., Burkhardt, D. and Little, C. ( 1998) Evaluation of the effects of diacerhein in the sheep model of arthritis. Rev Prat48: S24-S30.
20.
Glasson, S.S., Askew, R., Sheppard, B., Carito, B., Blanchet, T., Ma, H.L. et al. (2005) Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature434: 644-648.
21.
Hilal, G., Martel-Pelletier, J., Pelletier, J.P., Ranger, P. and Lajeunesse, D. ( 1998) Osteoblast-like cells from human subchondral osteoarthritic bone demonstrate an altered phenotype in vitro: possible role in subchondral bone sclerosis. Arthritis Rheum41: 891-899.
22.
Hilal, G., Martel-Pelletier, J., Pelletier, J.P., Duval, N. and Lajeunesse, D. ( 1999) Abnormal regulation of urokinase plasminogen activator by insulin-like growth factor 1 in human osteoarthritic subchondral osteoblasts . Arthritis Rheum42: 2112-2122.
23.
Hwa, S.Y., Burkhardt, D., Little, C. and Ghosh, P. ( 2001) The effects of orally administered diacerein on cartilage and subchondral bone in an ovine model of osteoarthritis. J Rheumatol28: 825-834.
24.
Ji, J.D., Cheon, H., Jun, J.B., Choi, S.J., Kim, Y.R., Lee, Y.H. et al. (2001) Effects of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) on the expression of inflammatory cytokines and apoptosis induction in rheumatoid synovial fibroblasts and monocytes. J Autoimmun17: 215-221.
25.
Kobayashi, T., Notoya, K., Naito, T., Unno, S., Nakamura, A., Martel-Pelletier, J. et al. (2005) Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs. Arthritis Rheum52: 479-487.
26.
Kwan Tat, S., Pelletier, J.P., Lajeunesse, D., Fahmi, H., Lavigne, M. and Martel-Pelletier, J. ( 2008) The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. Clin Exp Rheumatol26: 295-304.
27.
Legendre, F., Bogdanowicz, P., Martin, G., Domagala, F., Leclercq, S., Pujol, J.P. et al. (2007) Rhein, a diacerhein-derived metabolite, modulates the expression of matrix degrading enzymes and the cell proliferation of articular chondrocytes by inhibiting ERK and JNK-AP-1 dependent pathways. Clin Exp Rheumatol25: 546-555.
28.
Legendre, F., Heuze, A., Boukerrouche, K., Leclercq, S., Boumediene, K., Galera, P. et al. (2009) Rhein, the metabolite of diacerhein, reduces the proliferation of osteoarthritic chondrocytes and synoviocytes without inducing apoptosis . Scand J Rheumatol38: 104-111.
29.
Martel-Pelletier, J., McCollum, R., Di Battista, J.A., Faure, M.P., Chin, J.A., Fournier, S. et al. (1992) The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as the type I receptor and analysis of binding kinetics and biologic function. Arthritis Rheum35: 530-540.
30.
Martel-Pelletier, J., Mineau, F., Jolicoeur, F.C., Cloutier, J.M. and Pelletier, J.P. ( 1998) In vitro effects of diacerhein and rhein on IL-1 and TNF-alpha systems in human osteoarthritic tissues. J Rheumatol25: 753-762.
31.
Martel-Pelletier, J., Lajeunesse, D. and Pelletier, J.P. ( 2005) Etiopathogenesis of osteoarthritis, In: Koopman, W.J. and Moreland, L.W. (eds), Arthritis & allied conditions. A textbook of rheumatology, Lippincott, Williams & Wilkins: Baltimore, pp. 2199-2226.
32.
Martel-Pelletier, J., Lajeunesse, D., Reboul, P. and Pelletier, J.P. ( 2007) The role of subchondral bone in osteoarthritis, In: Sharma, L. and Berenbaum, F. (eds), Osteoarthritis: a companion to rheumatology, MosbyElsevier: Philadelphia, pp. 15-32.
33.
Martin, G., Bogdanowicz, P., Domagala, F., Ficheux, H. and Pujol, J.P. ( 2003) Rhein inhibits interleukin-1 beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappa B and AP-1 in chondrocytes cultured in hypoxia: a potential mechanism for its disease-modifying effect in osteoarthritis . Inflammation27: 233-246.
34.
Massicotte, F., Lajeunesse, D., Benderdour, M., Pelletier, J.-P., Hilal, G., Duval, N. et al. (2002) Can altered production of interleukin 1β, interleukin-6, transforming growth factor-β and prostaglandin E2 by isolated human subchondral osteoblasts identify two subgroups of osteoarthritic patients . Osteoarthritis Cartilage10: 491-500.
35.
Mazieres, B., Berdah, L., Thiechart, M. and Viguier, G. ( 1993) Diacetylrhein on a postcontusion model of experimental osteoarthritis in the rabbit. Rev Rhum Ed Fr60: 77S-81S.
36.
Mazieres, B., Blanckaert, A., Thiechart, M. and Viguier, G. ( 1996) Diacetylrhein administrated ‘curatively’ in an experimental model of post-contusion osteoarthritis in rabbits. Rev Prat46: S42-S45 (abstract).
37.
McCollum, R., Martel-Pelletier, J., Di Battista, J.A. and Pelletier, J.P. ( 1991) Regulation of interleukin 1 receptors in human articular chondrocytes. J Rheumatol18: 85-88.
38.
Moldovan, F., Pelletier, J.P., Jolicoeur, F.C., Cloutier, J.M. and Martel-Pelletier, J. ( 2000) Diacerhein and rhein reduce the ICE-induced IL-1beta and IL-18 activation in human osteoarthritic cartilage. Osteoarthritis Cartilage8: 186-196.
39.
Moore, A.R., Greenslade, K.J., Alam, C.A. and Willoughby, D.A. ( 1997) Effects of diacerhein on cytokine determinations in a model of cartilage degradation induced by granuloma in mice. Rev Prat47: S24-S26 (abstract).
40.
Moore, A.R., Greenslade, K.J., Alam, C.A. and Willoughby, D.A. ( 1998) Effects of diacerhein on granuloma induced cartilage breakdown in the mouse. Osteoarthritis Cartilage6: 19-23.
41.
Nicolas, P., Tod, M., Padoin, C. and Petitjean, O. ( 1998) Clinical pharmacokinetics of diacerein. Clin Pharmacokinet35: 347-359.
42.
Petitjean, O., Tod, M. and Louchahi, K. ( 1991) Étude de la pharmacocinétique de l’ART 50® en administration aigüe orale a la dose de 50 mg chez le volontaire sain âgé de 61-70 ans et de plus de 70 ans, et en administration réitérée a la dose de 50 mg x 2/jour chez le volontaire âgé de plus de 70 ans. Latoratoires NEGMA, Study PC/ART 9013N . Study report, April 1991.
43.
Pelletier, J.P., Mineau, F., Fernandes, J.C., Duval, N. and Martel-Pelletier, J. ( 1998) Diacerhein and rhein reduce the interleukin 1 beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. J Rheumatol25: 2417-2424.
44.
Pelletier, J.P., Lajeunesse, D., Reboul, P., Mineau, F., Fernandes, J.C., Sabouret, P. et al. (2001) Diacerein reduces the excess synthesis of bone remodeling factors by human osteoblast cells from osteoarthritic subchondral bone. J Rheumatol28: 814-824.
45.
Pelletier, J.P., Mineau, F., Boileau, C. and Martel-Pelletier, J. ( 2003) Diacerein reduces the level of cartilage chondrocyte DNA fragmentation and death in experimental dog osteoarthritic cartilage at the same time that it inhibits caspase-3 and inducible nitric oxide synthase. Clin Exp Rheumatol21: 171-177.
46.
Pelletier, J.P., Raynauld, J.P., Berthiaume, M.J., Abram, F., Choquette, D., Haraoui, B. et al. (2007) Risk factors associated with the loss of cartilage volume on weight bearing areas in knee osteoarthritis patients assessed by quantitative MRI: a longitudinal study. Arthritis Res Ther9: R74.
47.
Pelletier, J.-P., Raynauld, J.-P., Abram, F., Haraoui, B., Choquette, D. and Martel-Pelletier, J. ( 2008) A new non-invasive method to assess synovitis severity in relation to symptoms and cartilage volume loss in knee osteoarthritis patients using MRI. Osteoarthritis Cartilage16: S8-S13.
48.
Pomarelli, P., Berti, M., Gatti, M.T. and Mosconi, P. ( 1980) A non-steroidal anti-inflammatory drug that stimulates prostaglandin release. Farmaco35: 836-842.
49.
Pujol, J.P., Felisaz, N., Boumediene, K., Ghayor, C., Herrouin, J.F., Bogdanowicz, P. et al. (2000) Effects of diacerein on biosynthesis activities of chondrocytes in culture. Biorheology37: 177-184.
50.
Raynauld, J.P., Kauffmann, C., Beaudoin, G., Berthiaume, M.J., de Guise, J.A., Bloch, D.A. et al. (2003) Reliability of a quantification imaging system using magnetic resonance images to measure cartilage thickness and volume in human normal and osteoarthritic knees. Osteoarthritis Cartilage11: 351-360.
51.
Raynauld, J.-P., Martel-Pelletier, J., Abram, J. and Pelletier, J.-P. ( 2008a) Use of quantitative magnetic resonance imaging (qMRI) in the cross-sectional and longitudinal evaluation of structural changes in knee osteoarthritis (OA) patients, In: Reid, D.M., Miller, C.G. and Baburaj, K. (eds), Clinical trials in rheumatoid arthritis and osteoarthritis, Springer-Verlag: London.
52.
Raynauld, J.-P., Martel-Pelletier, J., Berthiaume, M.-J., Abram, F., Choquette, D., Haraoui, B. et al. (2008b) Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period. Ann Rheum Dis67: 683-688.
53.
Raynauld, J.P., Martel-Pelletier, J., Berthiaume, M.J., Beaudoin, G., Choquette, D., Haraoui, B. et al. (2006) Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. Arthritis Res Ther8: R21.
54.
Raynauld, J.P., Martel-Pelletier, J., Berthiaume, M.J., Labonté, F., Beaudoin, G., de Guise, J.A. et al. (2004) Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes. Arthritis Rheum50: 476-487.
55.
Redini, F., Galera, P., Mauviel, A., Loyau, G. and Pujol, J.P. ( 1988) Transforming growth factor beta stimulates collagen and glycosaminoglycan biosynthesis in cultured rabbit articular chondrocytes. FEBS Lett234: 172-176.
56.
Rintelen, B., Neumann, K. and Leeb, B.F. ( 2006) A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med166: 1899-1906.
57.
Sadouk, M., Pelletier, J.P., Tardif, G., Kiansa, K., Cloutier, J.M. and Martel-Pelletier, J. ( 1995) Human synovial fibroblasts coexpress interleukin-1 receptor type I and type II mRNA: the increased level of the interleukin-1 receptor in osteoarthritic cells is related to an increased level of the type I receptor . Lab Invest73: 347-355.
58.
Saha, N., Moldovan, F., Tardif, G., Pelletier, J.P., Cloutier, J.M. and Martel-Pelletier, J. ( 1999) Interleukin-1beta-converting enzyme/Caspase-1 in human osteoarthritic tissues: localization and role in the maturation of IL-1beta and IL-18. Arthritis Rheum42: 1577-1587.
59.
Sanchez, C., Mathy-Hartert, M., Deberg, M.A., Ficheux, H., Reginster, J.Y. and Henrotin, Y.E. ( 2003) Effects of rhein on human articular chondrocytes in alginate beads. Biochem Pharmacol65: 377-388.
60.
Segré, G. ( 1988) Étude pilote du passage de la rhéine dans le liquide synovial. Laboratoires NEGMA, Study 4A29. Study report, July 1988.
61.
Simonin, M.A., Bordji, K., Boyault, S., Bianchi, A., Gouze, E., Becuwe, P. et al. (2002) PPAR-gamma ligands modulate effects of LPS in stimulated rat synovial fibroblasts. Am J Physiol Cell Physiol282: C125-C133.
62.
Smith Jr, G.N., Myers, S.L., Brandt, K.D., Mickler, E.A. and Albrecht, M. ( 1999) Diacerhein treatment reduces the severity of osteoarthritis in the canine cruciate-deficiency model of osteoarthritis. Arthritis Rheum42: 545-554.
63.
Sokoloff, L. ( 1993) Microcracks in the calcified layer of articular cartilage . Arch Pathol Lab Med117: 191-195.
64.
Spencer, C.M. and Wilde, M.I. ( 1997) Diacerein. Drugs53: 98-108.
65.
Stanton, H., Rogerson, F.M., East, C.J., Golub, S.B., Lawlor, K.E., Meeker, C.T. et al. (2005) ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature434: 648-652.
66.
Tamura, T. and Ohmori, K. ( 2001) Rhein, an active metabolite of diacerein, suppresses the interleukin-1alpha-induced proteoglycan degradation in cultured rabbit articular chondrocytes. Jpn J Pharmacol85: 101-104.
67.
Tamura, T., Shirai, T., Kosaka, N., Ohmori, K. and Takafumi, N. ( 2002) Pharmacological studies of diacerein in animal models of inflammation, arthritis and bone resorption. Eur J Pharmacol448: 81-87.
68.
Yaron, M., Shirazi, I. and Yaron, I. ( 1999) Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures. Osteoarthritis Cartilage7: 272-280.
